Active	Status	Sponsor type	Region	Phase	Filter
8 Active 2 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zhu, Jay-Jiguang
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study) Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma	Recruiting	3	450	Europe, Canada, Japan, US, RoW	Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo	Chimerix	H3 K27M, Glioma	08/26	08/26
NCT04762069 / 2021-003659-40: A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme Jan 2023 - Jun 2023 : Data from trial for glioblastoma Jul 2022 - Dec 2022 : Interim analysis data from trial for glioblastoma in adults	Active, not recruiting	2	210	Europe, US	Berubicin, Berubicin Hydrochloride, Lomustine, Lomustine Capsules, CCNU, CeeNU, Gleostine	CNS Pharmaceuticals, Inc., Worldwide Clinical Trials	Glioblastoma Multiforme, Adult	12/24	03/25
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas	Recruiting	2	124	US	Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib	Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation	Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation	01/26	01/28
NCT04190628: Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors	Terminated	1	53	US	ABM-1310, ABM1310, Cobimetinib, Cotellic®	ABM Therapeutics Corporation	Advanced Solid Tumor, BRAF V600 Mutation	04/24	04/24
NCT03115333: DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma	Recruiting	N/A	146	US	Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, DSC-MRI, Dynamic Susceptibility Contrast-Enhanced MRI, DYNAMIC SUSCEPTIBILITY-CONTRAST MRI	ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)	Gliosarcoma, Recurrent Glioblastoma	05/25	05/27
NCT06062446: A Prospective Study of a Modified Lumbar Puncture (LP) Procedure That Reduces Post-Lumbar Puncture Headaches (PLPH) in Patients	Recruiting	N/A	100	US	Modified Lumbar Puncture	The University of Texas Health Science Center, Houston	Post-Lumbar Puncture Headache	08/25	08/25
Vu, Mia
GESTALT, NCT05342883: GammaTile and Stupp in Newly Diagnosed GBM	Recruiting	4	61	US	Surgical tumor resection, GammaTile radiation therapy implantation, Stupp protocol (EBRT and Temozolamide)	GT Medical Technologies, Inc.	Glioblastoma	07/27	12/27
NCT04190628: Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors	Terminated	1	53	US	ABM-1310, ABM1310, Cobimetinib, Cotellic®	ABM Therapeutics Corporation	Advanced Solid Tumor, BRAF V600 Mutation	04/24	04/24